BioCardia, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $0 | $58,000 | $477,000 | $1.4M | $1.0M |
| Operating income | -$8.3M | -$8.0M | -$11.6M | -$11.9M | -$12.6M |
| Cost of revenue | — | — | — | — | $0 |
| Cash from operations | -$7.4M | -$7.9M | -$10.0M | -$10.6M | -$10.4M |
| Capital expenditure | $7,000 | $6,000 | $12,000 | $70,000 | $116,000 |
| Free cash flow | -$7.4M | -$7.9M | -$10.0M | -$10.6M | -$10.5M |
| Impairments | — | — | — | — | $0 |
| Total assets | $3.4M | $3.7M | $3.0M | $9.8M | $15.7M |
| Total liabilities | $2.5M | $2.9M | $4.6M | $4.9M | $5.3M |
Shares outstanding 11.4M · Free float 81.5%
Annual filing data through FY ended December 31, 2025; float as of July 11, 2026.